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Introduction {#sec005}
============

Sub-Saharan Africa is by far the most affected region of the world by the HIV pandemic, with 25.8 million of people living with HIV (69.9% of the total) \[[@pone.0170753.ref001]\]. However, during the last decade, access to antiretroviral treatment (ART) has substantially improved in this part of the world and in 2014, 10.7 million of HIV-infected people (41.5% of the world total) were receiving ART in sub-Saharan Africa, an increase of 20% from 2010 \[[@pone.0170753.ref002]\]. These figures (absolute number and proportion) are likely to increase thanks to the recent World Health Organization (WHO) guidelines which recommends to initiate ART in all adults living with HIV regardless of CD4 cell count \[[@pone.0170753.ref003]\].

Facing an unprecedented number of people initiating ART in sub-Saharan Africa, the monitoring of treatment-related toxicity must be adapted to inform recommendations for the use of ART. Indeed, in low and middle-income countries long-term safety data of ART is still limited due to the lack of pharmacovigilance systems. Nevertheless, adverse events related to ART are common and represent the first cause of treatment modification in HIV-infected people on ART in sub-Saharan Africa \[[@pone.0170753.ref004],[@pone.0170753.ref005]\]. The WHO classifies ART related toxicities into four grades of severity. In case of severe toxicity (grade 3--4) it is usually recommended to remove the incriminated drug. Mild or moderate neutropenia are usually asymptomatic but when severe, can lead to life-threatening infectious conditions and thus fit the grade 3--4 toxicity classification. Several studies have shown an increased risk of bacterial and fungal infections in HIV-infected people with neutropenia, most of them being conducted in the pre-ART era in industrialized countries \[[@pone.0170753.ref006]--[@pone.0170753.ref010]\]. In addition, a study has also revealed an increased risk of mortality associated with neutropenia in Spanish patients living with HIV \[[@pone.0170753.ref011]\].

Etiological factors leading to neutropenia in patients with HIV infection are multiple. Indeed, neutropenia can occur as a direct consequence of HIV infection and its related immunodeficiency, usually in the late stages of the HIV disease \[[@pone.0170753.ref012]\]. Another cause of neutropenia in people living with HIV is the use of myelotoxic agents. Despite the WHO 2013 guidelines recommending to treat everyone with tenofovir (TDF) in first-line \[[@pone.0170753.ref013]\], zidovudine (ZDV), one of the first-line antiretroviral drugs recommended since 2000, is still massively used.

There have been several studies reporting the impact of ZDV on developing neutropenia in a context of no or limited access to ART \[[@pone.0170753.ref014]--[@pone.0170753.ref017]\]. Other drugs such as cotrimoxazole (CTX), which is part of the minimal package of care for the prevention of opportunistic infection in people living with HIV, has also been shown to be a common cause of neutropenia \[[@pone.0170753.ref017]--[@pone.0170753.ref019]\].

In West Africa, where ZDV is still the usual drug in first-line ART regimens, there is a need to document the occurrence of hematologic toxicity in real-life conditions. The main objective of this study was to estimate the incidence of severe neutropenia and associated factors in people living with HIV initiating ART in West Africa.

Methods {#sec006}
=======

Study population {#sec007}
----------------

The present analysis was conducted within the International Epidemiologic Databases to Evaluate AIDS (IeDEA) in West Africa consortium ([www.iedea.org/](http://www.iedea.org/)) that aims at collecting a large set of data necessary for clinical and epidemiological research in the context of ART use \[[@pone.0170753.ref020]\]. This collaboration currently involves 17 HIV clinics from nine countries: Benin, Burkina Faso, Côte d'Ivoire, Ghana, Guinea-Bissau, Mali, Nigeria, Senegal and Togo. The IeDEA West Africa database maintains individual records related to socio-demographic, clinical and biological data of patients at ART initiation and during follow-up visits in participating health facilities. In each health center, patients are expected to have full blood count and selected biological tests at ART initiation and every six months thereafter. Data generated by these HIV clinics are reported, once a year, to the regional center based in Abidjan, Côte d'Ivoire using a standardized data format allowing data merging.

Adult patients (age ≥16 years) living with HIV and initiating a first-line ART regimen between 2002 and 2014 that contained three or more drugs, had an absolute neutrophil count (ANC) \>750 cells/mm^3^ within six months prior to ART initiation and at least one follow-up ANC in the first six months on ART were included. HIV clinics not reporting ANC within their database were excluded from this project, leading a total of eight HIV clinics participating in this analysis: the Centre National Hospitalier Universitaire de Cotonou (CNHU) in Benin, the Centre Hospitalier Universitaire Souro Sanou of Bobo Dioulasso (BOBO) and the Service de Médecine interne du Centre Hospitalier Universitaire Yalgado Ouedraogo (CHUYO) in Burkina Faso, the Centre de Prise en charge de Recherche et de Formation de l'Hôpital Yopougon Attié (CePReF) of Abidjan, the Centre Médical de Suivi de Donneurs de Sang (CNTS) of Abidjan and the MTCT-Plus Program (MTCTP) of Abidjan in Côte d'Ivoire, the Service d'Hépato-Gastro-Entérologie du Centre Hospitalier Universitaire Yalgado Ouedraogo of Bamako (Gabriel Toure) in Mali and the Service de Maladies Infectieuses et Tropicales du Centre Hospitalier Universitaire de Fann in Dakar (SMITD) in Senegal.

Data collection and outcome definition {#sec008}
--------------------------------------

For the present analysis, characteristics extracted from the IeDEA West Africa database were gender, date of birth, height, weight, ART regimen, clinical staging (either WHO or CDC definition), CD4 cell count and full blood count. Baseline was defined as the date of ART initiation.

The primary outcome of this study was severe neutropenia. Neutropenia was classified according to the NIH Division of AIDS scale: grade 1 (ANC \<1,300 cells/mm^3^), grade 2 (ANC \<1,000 cells/mm^3^), grade 3 (ANC \<750 cells/mm^3^), and grade 4 (ANC \<500 cells/mm^3^) \[[@pone.0170753.ref021]\]. Severe neutropenia was defined as an ANC ≤750 cells/mm^3^ (grade 3 or 4). The main exposure was ART and more specifically the use of ZDV. Exposure to ZDV was considered as a time-updated variable in order to take into account ART modifications over time. The cumulated exposure to ZDV was then classified into four categories: not exposed (reference group), exposed ≤6 months, exposed\] 6--12 months\] and exposed \>12 months.

Ethical considerations {#sec009}
----------------------

The IeDEA West Africa Collaboration obtained authorization from the Ethics committee "Comité de Protection des Personnes Sud-Ouest et Outre-mer III" (N° 06--09) in Bordeaux, France, and from the national ethics committees of each participating countries: Benin (IRB 00006860), Burkina Faso (N° 2011-8-46), Cote d'Ivoire (IRB 00009111), Senegal (IRB 00002659) and Mali (IRB 00001465). A waiver for individual informed consent was given by the Institutional Review Boards as the data was collected from routine patients\' charts. The study procedure did not involve any personal contact with the patients.

Statistical analysis {#sec010}
--------------------

The baseline characteristics were summarized using descriptive statistics. Missing values at baseline were imputed by the most updated data within a range of three months and data still missing were treated as a specific category. Longitudinal data from patients with a baseline ANC measure and at least one ANC measure after six month were computed to estimate the incidence rate of severe neutropenia and evaluate the factors associated with the occurrence of neutropenia. The incidence rate was defined as the number of patients with a first episode of severe neutropenia per 100 person-years (PY) of follow-up. Poisson regression method was used to estimate the incidence rate of neutropenia with its 95% confidence interval (CI). Incidence rates were adjusted for HIV clinic, gender, age, calendar year for ART initiation, baseline neutrophil count, baseline hemoglobin level, baseline CD4 count, first-line ART regimen and baseline clinical stage.

The role of ART and other characteristics in the development of first-time neutropenia was analyzed by univariate and multivariate Cox proportional hazards regression models. All the explanatory variables were considered at baseline except ZDV exposure and CD4 count that were computed as time-updated variables. In order to take into account time-updated variables we did a counting process format style of input which consists of a sequence of time intervals over which the values of any time-varying explanatory variable are constant for each participating individual. The final multivariate Cox regression model was stratified on HIV clinic and only significant variables (p \<0.05) and possible confounding factors were kept in the model. Each patient contributed to the time at risk from the time they entered into the study (i.e. the date of ART initiation) either until the closing date (December 31^st^, 2014), date of death or loss-to-follow-up, date of transfer out, date of last visit with ANC available in an interval of six months or date of first severe neutropenia. We restricted the analysis for a two-year period after ART initiation. In addition, we described the ART modifications that occurred in the month following the development of severe neutropenia.

All statistical analysis was performed with the SAS 9.4 software (SAS Institute Inc., Cary, NC, USA).

Results {#sec011}
=======

Of the 25,833 patients with at least one ANC measure available enrolled in the participating IeDEA West Africa cohorts between 2002 and 2014, 15,456 (60%) had an ANC measure available at baseline (ART initiation). Of these, 9,880 (65%) had at least another ANC during the first six months but 454 of them were excluded because of severe neutropenia at ART initiation. Overall, 9,426 patients were included in this analysis ([Fig 1](#pone.0170753.g001){ref-type="fig"}).

![Study population flow chart.\
ANC, absolute neutrophil count; ART, antiretroviral therapy.](pone.0170753.g001){#pone.0170753.g001}

Patients with at least one ANC measure available but who were excluded (n = 16,407) initiated ART in earlier calendar year than the 9,426 patients included in the analysis (median year: 2008 versus 2009; p \<10^−4^). Conversely, there were no significant differences concerning age (p = 0.11), gender (p = 0.20), baseline CD4 count (p = 0.18) and ART regimen distribution (p = 0.49) ([S1 Table](#pone.0170753.s001){ref-type="supplementary-material"}).

Baseline characteristics of the included patients are shown in [Table 1](#pone.0170753.t001){ref-type="table"}; 70% were women and the median age was 37 years \[Inter-quartile Range (IQR): 31--44\]. The median calendar year for ART initiation was 2009 \[IQR: 2006--2011\]. The median CD4 count at ART initiation was 174 cells/mm^3^ \[IQR: 80--278\]. The proportion of patient with either CDC stage 3 or WHO stage 4 was 16.5%. Grade 1 neutropenia was reported in 11% at ART initiation and grade 2 neutropenia in 5%. The median hemoglobin level was 10g/dL \[IQR: 9--12\]. Moderate and severe anemia was found in 25% and 7% of included patients, respectively. A ZDV-containing ART regimen was initiated in 5,081 (54%) patients.

10.1371/journal.pone.0170753.t001

###### Patient's characteristics at ART initiation.

IeDEA West Africa collaboration, 2002--2015 (N = 9,426).
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  Characteristics                                        All (N = 9,426)   
  ------------------------------------------------------ ----------------- ----------------
  **HIV clinic, Country; n (%)**                                           
   CePReF, Cote d'Ivoire                                 3,529             (37.4)
   CNTS, Cote d'Ivoire                                   1,502             (15.9)
   MTCTP, Cote d'Ivoire                                  462               (4.9)
   BOBO, Burkina Faso                                    1,956             (20.8)
   CHUYO, Burkina Faso                                   279               (3.0)
   CNHU, Benin                                           816               (8.7)
   Gabriel Toure, Mali                                   559               (5.9)
   SMITD, Senegal                                        323               (3.4)
  **Calendar year for ART initiation; median \[IQR\]**   2009              \[2006--2011\]
  **Gender; n (%)**                                                        
   Female                                                6,598             (70.0)
   Male                                                  2,828             (30.0)
  **Age (years); n (%)**                                                   
   \<35                                                  4,024             (42.7)
    ≥35                                                  5,402             (57.3)
  **Clinical stage (CDC 3 or WHO 4); n (%)**                               
   No                                                    5,930             (62.9)
   Yes                                                   1,557             (16.5)
   Missing                                               1,939             (20.6)
  **CD4 count (cells/mm**^**3**^**); n (%)**                               
   \<350                                                 7,314             (77.6)
   ≥350                                                  1,122             (11.9)
   Missing                                               990               (10.5)
  **Neutrophils count (cells/mm**^**3**^**); n (%)**                       
   ≥1,300                                                7,944             (84.3)
   1,000--1,300                                          1,034             (11.0)
   750--1,000                                            448               (4.8)
  **Hemoglobin level (g/dL); n (%)**                                       
   ≥10                                                   5,974             (63.4)
   7.5--10                                               2,307             (24.5)
   \<7.5                                                 629               (6.7)
   Missing                                               516               (5.5)
  **ART regimen containing ZDV; n (%)**                                    
   No                                                    4,345             (46.1)
   Yes                                                   5,081             (53.9)
  **First-line ART regimen; n (%)**                                        
   ZDV/3TC/EFV                                           2,195             (23.3)
   ZDV/3TC/NVP                                           2,307             (24.5)
   D4T/3TC/EFV                                           819               (8.7)
   D4T/3TC/NVP                                           1,426             (15.1)
   TDF-based regimens                                    1,590             (16.9)
   Other regimens                                        1,089             (11.6)

IQR, interquartile range; CI, confidence interval; ART, antiretroviral therapy; CDC, US Centers for Disease Control; WHO, World Health Organization; ZDV, zidovudine; 3TC, lamivudine; EFV, efavirenz; D4T, stavudine; NVP, nevirapine; TDF, tenofovir; FTC, emtricitabine.

As depicted in [Fig 2](#pone.0170753.g002){ref-type="fig"}, the proportion of patients initiating a D4T-containing regimen in our study population fell from 50% between 2002 and 2008 to 12% during the period 2009--2011 and to only 1% for the period 2012--2014. This decreased was compensated by an increased prescription of ZDV and tenofovir (TDF)-containing regimens. Indeed, before 2009, ZDV was prescribed just as much as D4T and its proportion increased to \>60% for the period 2012--2014 and remained the most frequently prescribed combination since then. The proportion of patients initiating a TDF-containing regimen increased from \<8% before 2009 to 27% for the period 2009--2011 and 32% for the period 2012--2014.

![Distribution of first-line antiretroviral regimens prescribed according to calendar period.\
**IeDEA West Africa collaboration, 2002--2014 (N = 9,426)**. ZDV, zidovudine; D4T, stavudine; NVP, nevirapine; TDF, tenofovir.](pone.0170753.g002){#pone.0170753.g002}

Incidence of severe neutropenia {#sec012}
-------------------------------

From 2002 to 2014, the 9,426 patients enrolled contributed to 9,724 person-years of follow-up. The median participation time was 12 months \[IQR: 6--20\] during which 888 patients presented at least one episode of severe neutropenia. The overall incidence rate of severe neutropenia was estimated at 9.1 per 100 PY (95% CI: 8.6--9.8) ([Table 2](#pone.0170753.t002){ref-type="table"}). This estimate was significantly different between HIV clinics (p \<10^−4^), from 3.5 per 100 PY in BOBO, Burkina Faso to 13.0 in CePReF, Cote d'Ivoire. The incidence was also significantly higher in patients exposed to an ART regimen containing ZDV (p \<10^−4^), starting ART with a CD4 count \<350 cells/mm^3^ (p \<10^−4^), at clinical stage CDC 3 or WHO 4 (p \<10^−3^) and in patients with neutropenia of grade 1 or 2 (p \<10^−4^). The neutropenia rate in patients who initiated ART after 2005 was lower than in patients who initiated ART between 2002 and 2005. The occurrence of severe neutropenia did not differ by gender, age and baseline hemoglobin level.

10.1371/journal.pone.0170753.t002

###### Incidence of severe neutropenia among 9,426 HIV-infected patients over a two-year period after ART initiation.

IeDEA West Africa collaboration, 2002--2015.

![](pone.0170753.t002){#pone.0170753.t002g}

  Characteristic                                         No. patients   No. of first neutropenia / PY   Rate (95% CI) per 100 PY   p
  ------------------------------------------------------ -------------- ------------------------------- -------------------------- ----------
  **HIV clinic, Country**                                                                                                          \<10^−4^
   CePReF, Cote d'Ivoire                                 3,529          481/3,701                       13.0 (11.9--14.2)          
   CNTS, Cote d'Ivoire                                   1,502          141/1,766                       8.0 (6.8--9.4)             
   MTCTP, Cote d'Ivoire                                  462            50/386                          13.0 (9.8--17.1)           
   BOBO, Burkina Faso                                    1,956          93/2,638                        3.5 (2.9--4.3)             
   CHUYO, Burkina Faso                                   279            18/155                          11.7 (7.3--18.5)           
   CNHU, Benin                                           816            46/446                          10.3 (7.7--13.8)           
   Gabriel Toure, Mali                                   559            33/405                          8.1 (5.8--11.5)            
   SMITD, Senegal                                        323            26/228                          11.4 (7.8--16.8)           
  **Gender**                                                                                                                       0.50
   Male                                                  2,828          265/2,828                       9.5 (8.4--10.7)            
   Female                                                6,598          623/6,923                       9.0 (8.0--9.7)             
  **Age (years)**                                                                                                                  0.39
   \<35                                                  4,024          364/4,123                       8.8 (8.0--9.8)             
   ≥35                                                   5,402          524/5,601                       9.3 (8.6--10.2)            
  **Calendar year for ART initiation**                                                                                             \<10^−4^
   2002--2005                                            2,259          327/2,270                       14.4 (12.9--16.1)          
   2006--2008                                            2,256          193/2,485                       7.8 (5.8--10.3)            
   2009--2011                                            2,419          190/2,860                       6.6 (5.0--8.8)             
   2012--2014                                            2,492          178/2,110                       8.4 (6.3--11.3)            
  **Baseline neutrophils count (cells/mm**^**3**^**)**                                                  \<10^−4^                   
   ≥1,300                                                7,944          649/8,238                       7.9 (7.3--8.5)             
   1,000--1,300                                          1,034          145/1,064                       13.6 (11.6--16.0)          
   750--1,000                                            448            94/422                          22.3 (18.2--27.3)          
  **Baseline hemoglobin level (g/dL)**                                                                  0.56                       
   ≥10                                                   5,974          572/6,383                       9.0 (8.3--9.7)             
   \<10                                                  2,936          275/2,954                       9.3 (8.3--10.5)            
   Missing                                               516            41/387                          10.6 (7.8--14.4)           
  **Baseline CD4 count (cells/mm**^**3**^**)**                                                                                     \<10^−4^
    ≥350                                                 1,122          56/1,272                        4.4 (3.4--5.8)             
   \<350                                                 7,314          753/7,512                       10.0 (9.3--10.8)           
   Missing                                               990            79/941                          3.7 (2.6--5.2)             
  **Initial ART regimen containing ZDV**                                                                \<10^−4^                   
   No                                                    4,345          333/4,353                       7.7 (6.9--8.5)             
   Yes                                                   5,081          555/5,372                       10.3 (9.5--11.2)           
  **First-line ART regimen**                                                                                                       \<10^−4^
   ZDV/3TC/EFV                                           2,195          264/2,281                       11.6 (10.3--13.1)          
   ZDV/3TC/NVP                                           2,307          240/2,433                       9.9 (8.7--11.2)            
   D4T/3TC/EFV                                           819            86/833                          10.3 (8.4--12.8)           
   D4T/3TC/NVP                                           1,426          127/1,446                       8.8 (7.4--10.5)            
   TDF-based regimens                                    1,590          85/1,542                        5.5 (4.5--6.8)             
   Other regimens                                        1,089          86/1,189                        7.2 (5.9--8.9)             
  **Baseline clinical stage (CDC 3 or WHO 4)**                                                          \<10^−3^                   
   No                                                    5,930          527/6,184                       8.5 (7.8--9.3)             
   Yes                                                   1,557          184/1,552                       11.9 (10.3--13.7)          
   Missing                                               1,939          177/1,988                       8.9 (7.7--10.3)            

PY, person-year; CI, confidence interval; ART, antiretroviral therapy; CDC, US Centers for Disease Control; WHO, World Health Organization; ZDV, zidovudine; 3TC, lamivudine; EFV, efavirenz; D4T, stavudine; NVP, nevirapine; TDF, tenofovir; FTC, emtricitabine; CTX, cotrimoxazole.

Factors associated with severe neutropenia {#sec013}
------------------------------------------

The results of Cox regression models are shown in [Table 3](#pone.0170753.t003){ref-type="table"}. The risk to develop a first episode of severe neutropenia was significantly higher in patient exposed to ZDV compared to those initiating another first-line ART regimen, irrespective of their time spent on ZDV:\] 0--6\] months (adjusted hazard ratio (aHR) = 2.15; 95% CI: 1.81--2.56),\] 6--12\] months (aHR = 2.09; 95% CI: 1.60--2.72) and \>12 months (aHR = 1.62; 95% CI: 1.18--2.22) ([Table 3](#pone.0170753.t003){ref-type="table"}). The presence of a mild or moderate neutropenia at baseline was associated with an increased risk of subsequent episode of severe neutropenia. Other factors associated with the occurrence of severe neutropenia were: initiating ART between 2009 and 2011 (aHR = 0.73; 95% CI: 0.60--0.91) or between 2012 and 2014 (aHR = 0.55; 95% CI: 0.44--0.69) compared to initiation before 2005; an advanced clinical stage (CDC 3 or WHO 4) at ART initiation (aHR = 1.21; 95% CI: 1.02--1.44); and time-updated CD4 count \<350 cells/mm^3^ (aHR = 1.26; 95% CI: 1.07--1.49) compared with CD4 count ≥350cells/mm^3^.

10.1371/journal.pone.0170753.t003

###### Cox regression univariate and multivariate models estimating risk of severe neutropenia within two years after ART initiation.

IeDEA West Africa collaboration, 2002--2014 (N = 9,426).
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  Characteristic                                         Univariate analysis   Multivariate analysis[^1^](#t003fn001){ref-type="table-fn"}                                  
  ------------------------------------------------------ --------------------- ------------------------------------------------------------- ---------- ------ ------------ ----------
  **Time-updated exposure to ZDV (months)**                                                                                                  \<10^−4^                       \<10^−4^
   0 (Not exposed)                                       1                     Ref.                                                                     1      Ref.         
   \]0--6\]                                              1.80                  1.52--2.14                                                               2.15   1.81--2.56   
   \]6--12\]                                             1.81                  1.39--2.35                                                               2.09   1.60--2.72   
   \>12                                                  1.37                  1.01--1.86                                                               1.62   1.18--2.22   
  **Calendar year for ART initiation**                                                                                                       \<10^−4^                       \<10^−4^
   2002--2005                                            1                     Ref.                                                                     1      Ref.         
   2006--2008                                            0.56                  0.47--0.66                                                               0.87   0.71--1.06   
   2009--2011                                            0.49                  0.41--0.59                                                               0.73   0.60--0.91   
   2012--2014                                            0.56                  0.46--0.67                                                               0.55   0.44--0.69   
  **Baseline neutrophils count (cells/mm**^**3**^**)**                                                                                       \<10^−4^                       \<10^−4^
   ≥1,300                                                1                     Ref.                                                                     1      Ref.         
   1,000--1,300                                          1.72                  1.44--2.06                                                               1.52   1.27--1.82   
   750--1,000                                            2.74                  2.20--3.40                                                               2.47   1.99--3.07   
  **Baseline hemoglobin level (g/dL)**                                                                                                       0.86                           0.25
   ≥10                                                   1                     Ref.                                                                     1      Ref.         
   \<10                                                  1.03                  0.89--1.19                                                               1.13   0.97--1.32   
   Missing                                               1.07                  0.78--1.47                                                               0.90   0.55--1.47   
  **Clinical stage (CDC 3 or WHO 4) at initiation**                                                                                          \<10^−4^                       \<0.01
   No                                                    1                     Ref.                                                                     1      Ref.         
   Yes                                                   1.39                  1.17--1.64                                                               1.21   1.02--1.44   
   Missing                                               1.04                  0.88--1.24                                                               1.59   1.08--2.34   
  **Time-updated CD4 count (cells/mm**^**3**^**)**                                                                                           \<10^−4^                       \<0.01
    ≥350                                                 1                     Ref.                                                                     1      Ref.         
   \<350                                                 1.41                  1.19--1.66                                                               1.26   1.07--1.49   
   Missing                                               1.11                  0.85--1.46                                                               1.57   1.11--2.22   

^1^Analyses were stratified on HIV clinics.

HR, hazard ratio; aHR, adjusted hazard ratio; CI, confidence interval; ZDV, zidovudine; CDC, US Centers for Disease Control; WHO, World Health Organization.

Thereafter, we looked at ART modification after a first episode of severe neutropenia ([Table 4](#pone.0170753.t004){ref-type="table"}). Of the 888 patients with severe neutropenia, 128 (14.4%) had a change of ART regimen in the following month corresponding to a total of 134 drug modifications. The first drug stopped was ZDV (49%) followed by Nevirapine (24%). Among the 65 patients who stopped ZDV after severe neutropenia, 43% switched to D4T and 46% to TDF.

10.1371/journal.pone.0170753.t004

###### Distribution of antiretroviral modifications in HIV-infected patients with a first severe episode of neutropenia (n = 134).
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  Drug stopped   Distribution of modifications   Total                                                                
  -------------- ------------------------------- -------------- -------------- ------------ ------------ ------------ ---------
  ZDV            \-                              28 (43%)       30 (46%)       0 (0%)       0 (0%)       7 (11%)      65
  D4T            11 (61%)                        \-             2 (11%)        0 (0%)       0 (0%)       5 (28%)      18
  TDF            5 (71%)                         2 (29%)        \-             0 (0%)       0 (0%)       0 (0%)       7
  EFV            0 (0%)                          0 (0%)         0 (0%)         \-           8 (67%)      4 (33%)      12
  NVP            0 (0%)                          0 (0%)         0 (0%)         26 (81%)     \-           6 (19%)      32
  **Total**      **16 (12%)**                    **30 (22%)**   **32 (24%)**   **0 (0%)**   **0 (0%)**   **0 (0%)**   **134**

ZDV, zidovudine; 3TC, lamivudine; EFV, efavirenz; D4T, stavudine; NVP, nevirapine; TDF, tenofovir.

Discussion {#sec014}
==========

We found that the risk of developing severe neutropenia was associated with ZDV-containing ART regimen, initiating ART before 2009, having a low baseline neutrophil count, an advanced clinical stage and a more profound immune deficiency. In addition we found that the risk of severe neutropenia persisted over six months of treatment with ZDV-containing ART regimens in a context where the majority of ART initiation were based on ZDV including in the recent years, despite the change in WHO recommendations to replace it by TDF \[[@pone.0170753.ref013]\].

Our estimated incidence of severe neutropenia was higher than among patients living with HIV before access to ART in comparable settings. Indeed, the incidence rate of neutropenia reported by Toure *et al*. in a cohort study in Cote d'Ivoire was 4.3 per 100 PY after initiation of CTX prophylaxis \[[@pone.0170753.ref018]\]. Similarly, Anglaret *et al*. found an overall incidence rate of 1.9 per 100 PY during a CTX versus placebo clinical trial in Cote d'Ivoire and the incidence in the CTX arm was 2.8 per 100 PY \[[@pone.0170753.ref019]\]. Although theses variations might be related to methodological differences, they may also suggest that the incidence of severe neutropenia was lower in sub-Saharan Africa before access to ART. Conversely, our estimate is much lower than the rate of 56.3 per 100 PY found by Moh *et al*. in their cohort study in Cote d'Ivoire during the six months after ZDV-based ART initiation \[[@pone.0170753.ref022]\]. This variation can be explained by the fact that the majority of their study population (80%) was exposed to both ZDV and CTX prophylaxis at ART initiation, a combination known to increase the risk of severe neutropenia. As the impact of CTX on ANC is supposed to be acute, information on CTX use over time was needed to capture the impact of this molecule on neutropenia. Information on CTX exposure was incomplete in our study and we could not incorporate this variable in our analysis. Thus we could not fully compare our findings with the previous reports and their wide range of estimates of severe neutropenia.

We found an increased risk of severe neutropenia in patients exposed to ZDV and this risk was persistent after one year of treatment. These results are consistent with the known myelosuppressive effect of ZDV \[[@pone.0170753.ref014]--[@pone.0170753.ref017]\]. Hoffman *et al*. in South Africa reported an increased incidence of severe neutropenia after ZDV-based ART initiation in their cohort \[[@pone.0170753.ref017]\]. However, to the best of our knowledge, it is the first time that a study considers ZDV-exposure as a time-updated variable and quantifies the duration of exposure.

We also found that advanced immunodeficiency and advanced clinical stage were independent risk factors for severe neutropenia. These results are consistent with previous findings and emphasize the need of an early ART initiation as recently recommended by the WHO guidelines \[[@pone.0170753.ref003],[@pone.0170753.ref014],[@pone.0170753.ref018]\].

Finally, we found significant differences in the occurrence of severe neutropenia according to clinics. Several explanations may be formulated. The clinics participating to the IeDEA West Africa collaboration have their own organization and patient management procedures. Thus, the frequency of follow-up visits and biological measurements may vary substantially from one clinic to another, inducing a potential information bias. Second, unmeasured confounding factors associated with clinics might have influence the occurrence of severe neutropenia.

Despite the WHO recommendations suggesting to adapt the ART regimen when adverse effects of grade 3 or 4 occur, the rate of patients with severe neutropenia who changed ART regimen following neutropenia was low, leading to a few hypotheses. First, we were not able to document exposure to other drugs co-administered with ART such as CTX prophylaxis. CTX has a known acute hematologic toxicity and might be discontinued prior to any other drugs. If neutropenia resolves, CTX needs to be permanently evicted from patient's prescriptions and no additional ART modifications are needed. Secondly, the limited availability of alternative ART regimens might have prevented any ART modification in the absence of clinical consequences associated with severe neutropenia. Thirdly, the reported ANC might have not been properly graded, thus limiting the applications of guidelines recommendations. Indeed, a previous report from our collaboration in West Africa showed that only a limited number of ART prescribers declared grading adverse drug reactions \[[@pone.0170753.ref004]\].

We acknowledge several limitations to our study. First, we selected patients with at least one ANC at baseline and one ANC during the first six months of follow-up. It might have introduced a bias of selection if patients included and excluded were different. However, we found no significant differences between these two groups concerning the CD4 count and exposure to ZDV at ART initiation. Second, the occurrence of neutropenia is expected in patients initiating a ZDV-based ART regimen leading to a potential bias of information if these patients were better monitored. However, we did not find any significant differences concerning the number of follow-up visits and the duration of follow-up between patients exposed to ZDV and patients not exposed. Another important limitation was the lack of information concerning the exposure to CTX. Without this information we were not able to describe the combined impact of exposure to ZDV and CTX. In addition, we could not take into account the CTX prophylaxis interruptions in our description of treatment modifications after severe neutropenia.

Conclusion {#sec015}
==========

The incidence of severe neutropenia was high among people living with HIV on ART in West Africa. Initiating ART with a ZDV-based regimen was an important risk factor associated with the occurrence of a severe neutropenia and this risk persisted over time. In addition, an advanced HIV disease and a low CD4 count at ART initiation were also associated with a subsequent risk to develop a severe neutropenia.

The recent WHO guidelines recommend initiating a TDF-based ART regimen in HIV-infected persons regardless of their CD4 count. In a context where ZDV is still massively prescribed and most patients initiate ART at an advanced stage of the disease with low CD4 count, the implementation of the WHO recommendation will be crucial in order to reduce the risk of severe neutropenia.

Severe neutropenia is a known risk factor for bacterial infections although we were not able to document this clinical outcome in our population followed for a relatively short period of time. Thereafter, a better documentation of morbidity is needed in order to assess the potential impact of drug therapies on clinical outcomes among HIV-infected persons in sub-Saharan Africa.
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